Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents

Bibliography

• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009;59:56-66
   PubMed Web of Science ®Google Scholar
• Weingart SN, Brown E, Bach PB, NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw 2008;6(Suppl 3):S1-14
   PubMedGoogle Scholar
• Fleming TR, Mets DL. Surrogate end point in clinical trials. Ann Intern Med 1996;125:605-13
   PubMed Web of Science ®Google Scholar
• Chassany O, Sagnier P, Marquis P, Patient-reported outcomes: the example of health-related quality of life — a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002;36:209-38
   Web of Science ®Google Scholar
• Liu G, Franssen E, Fitch MI, Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-15
   PubMed Web of Science ®Google Scholar
• Borner MM, Schoffski P, de Wit R, Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomized crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-58
   PubMed Web of Science ®Google Scholar
• Wojtacki J, Wiraszka R, Rolka-Stempniewicz G, Breast cancer patients' preferences for oral versus intravenous second-line anticancer therapy. Eur J Cancer 2006;159:abstract 381
   Google Scholar
• Paley M, Love N, Carlson R, Preferences for oral and parenteral antitumor therapy: a survey of 260 patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2005;23:619
   PubMed Web of Science ®Google Scholar
• Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008;62:85-91
   PubMed Web of Science ®Google Scholar
• Kohne CH, Folprecht G. On prejudice and facts and choices. Ann Oncol 2006;17:185-7
   PubMed Web of Science ®Google Scholar
• McLeod HL, Evans WE. Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res 1999;5:2669-71
   PubMed Web of Science ®Google Scholar
• Gebbia V, Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 2005;4:915-28
   PubMedGoogle Scholar
• Molassiotis A, Brearley S, Sauders M, Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial. J Clin Oncol 2009;27:6191-8
   PubMed Web of Science ®Google Scholar
• Partridge AH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol 2006;17:183-4
   PubMed Web of Science ®Google Scholar
• Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2007;19:212-19
   PubMed Web of Science ®Google Scholar
• Rand CS. Measuring adherence with therapy for chronic diseases: implications for the treatment of heterozygous familial hypercholesterolemia. Am J Cardiol 1993;72:68D-74D
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-96
   PubMed Web of Science ®Google Scholar
• Haynes RB, Taylor DW, Sackett DL. Compliance in Health Care. Johns Hopkins University Press; Baltimore: 1979
   Google Scholar
• Sabate E. Adherence to long-term therapies. Evidence form action. World Health Organization (WHO); Geneva: 2003
   Google Scholar
• Cramer JA, Roy A, Burrell A, Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   PubMed Web of Science ®Google Scholar
• Rudd P. In search of the gold standard for compliance measurement. Arch Intern Med 1979;139:627-8
   PubMed Web of Science ®Google Scholar
• Levine AM, Richardson JL, Marks G, Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987;5:1469-77
   PubMed Web of Science ®Google Scholar
• Evans L, Spelman M. The problem of non-compliance with drug therapy. Drugs 1983;25:63-76
   PubMed Web of Science ®Google Scholar
• Tebbi CK. Treatment compliance in childhood and adolescence. Cancer 1993;71(10 Suppl):3441-9
   PubMed Web of Science ®Google Scholar
• Gauthier DK, Turner JG, Langley LG, Monitoring universal precautions: a new assessment tool. Infect Control Hosp Epidemiol 1991;12:597-601
   PubMed Web of Science ®Google Scholar
• Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet 1994;27:202-15
   PubMed Web of Science ®Google Scholar
• Festa RS, Tamaroff MH, Chasalow F, Lanzkowsky P. Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. J Pediatr 1992;120:807-11
   PubMed Web of Science ®Google Scholar
• Haynes RB, Taylor DW, Sackett DL, Can simple clinical measurements detect patient noncompliance? Hypertension 1980;2:757-64
   PubMed Web of Science ®Google Scholar
• Choo PW, Rand CS, Inui TS, Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999;37:846-57
   PubMed Web of Science ®Google Scholar
• Partridge AH, Archer L, Kornblith AB, Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010;28:2418-22
   PubMed Web of Science ®Google Scholar
• Avorn J, Monette J, Lacour A, Persistence of use of lipid-lowering medications: a cross-national study. J Am Med Assoc 1998;279:1458-62
   PubMed Web of Science ®Google Scholar
• Tindall WN, Boltri JM, Wilhelm SM. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. J Manag Care Pharm 2007;13:S2-S12
   PubMed Web of Science ®Google Scholar
• Waterhouse DM, Calzone KA, Mele C, Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993;11:1189-97
   PubMed Web of Science ®Google Scholar
• Veronesi A, Pizzichetta MA, Ferlante MA, Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatment. Tumori 1998;84:372-5
   PubMed Web of Science ®Google Scholar
• Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-15
   PubMed Web of Science ®Google Scholar
• Soran A, Nesbitt L, Mamounas EP, Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience. Clin Trials 2006;3:478-85
   PubMed Web of Science ®Google Scholar
• Partridge AH, Archer LE, Kornblith AB, CALGB 60104: adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907. Presented at the 2008 ASCO Annual Meeting; Chicago, Illinois, Dates; 2008
   Google Scholar
• Dezii CM. Medication noncompliance: what is the problem? Manag Care 2000;9:7-12
   PubMedGoogle Scholar
• Lebovits AH, Strain JJ, Schleifer SJ, Patient noncompliance with self-administered chemotherapy. Cancer 1990;65:17-22
   PubMed Web of Science ®Google Scholar
• Haynes RB. A critical review of the “determinants” of patient compliance with therapeutic regimens. In: Sackett DL, Haynes RB, editors. Compliance with Therapeutic Regimens. The Johns Hopkins University Press; Baltimore: 1976. p. 26-39
   Google Scholar
• Wang PS, Bohn RL, Knight E, Non-compliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Int Med 2002;17:504-11
   PubMed Web of Science ®Google Scholar
• World Helath Organization 2003. Available from: http://whqlibdoc.who.int/publications/ 2003/ 9241545992.pdf p. 1-169
   Google Scholar
• Schilsky RL, Hohneker J, Ratain MJ, Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 1998;16:1450-7
   PubMed Web of Science ®Google Scholar
• Nixon DW. Special aspects of cancer prevention trials. Cancer 1994;74(9 Suppl):2683-6
   PubMed Web of Science ®Google Scholar
• Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998;20:764-1
   PubMed Web of Science ®Google Scholar
• Cramer JA, Mattson RH, Prevey ML, Ouellette VL. How often is medication taken as prescribed? a novel assessment technique. JAMA 1989;261:3273-7
   PubMed Web of Science ®Google Scholar
• Llewellyn-Thomas H, Thiel E, McGreal MJ. Cancer patients' evaluations of their current health states: the influence of expectations, comparisons, actual health states and mood. Med Decis Making 1992;12:115-22
   PubMed Web of Science ®Google Scholar
• Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 1977;84:191-215
   PubMed Web of Science ®Google Scholar
• Kehoe WA, Katz RC. Health behaviors and pharmacotherapy. Ann Pharmacother 1998;32:1076-86
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Eisen SA, Miller DK, Woodward RS, The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4
   PubMed Web of Science ®Google Scholar
• Partridge AH, Wang PS, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6
   PubMed Web of Science ®Google Scholar
• Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988;6:1746-52
   PubMed Web of Science ®Google Scholar
• Lee CR, Nicholson PW, Souhami RL, Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 1992;10:1007-13
   PubMed Web of Science ®Google Scholar
• Ong LM, de Haes JC, Hoos AM, Lammes FB. Doctor-patient communication: a review of the literature. Soc Sci Med 1995;40:903-18
   PubMed Web of Science ®Google Scholar
• Golin CE, Liu H, Hays RD, A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756-65
   PubMed Web of Science ®Google Scholar
• Kee F. Patients' prerogatives and perceptions of benefit. Br J Med 1996;312:958-60
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• James R, Barni S, von Weikerstahl F, Improving chemotherapy capacity by switching from intravenous to oral vinorelbine: TAMINO, an international time and motion audit. Lung Cancer 2010;67(Suppl 1):S4
   PubMedGoogle Scholar
• Fung V, Mangione CV, Huang J, Turk N. Falling into the coverage gap: part D drug costs and adherence for medicare advantage prescription drug plan beneficiaries with diabetes. Health Serv Res 2009;45:355-75
   PubMed Web of Science ®Google Scholar
• Levine AM, Richardson JL, Marks G, Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987;5:1469-76
   PubMed Web of Science ®Google Scholar
• Sadahiro S, Ohki S, Yamaguchi S, Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. UFT Compliance Study Group, Kanagawa, Japan. Cancer Chemother Pharmacol 2000;46:180-4
   PubMed Web of Science ®Google Scholar
• Lee CR, Nicholson PW, Souhami RL, Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 1993;67:630-4
   PubMed Web of Science ®Google Scholar
• Lee CR, Nicholson PW, Ledermann JA, Rustin GJ. Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Eur J Gynaecol Oncol 1996;17:99-103
   PubMedGoogle Scholar
• Klein CE, Kastrissios H, Miller AA, Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 2006;57:199-206
   PubMed Web of Science ®Google Scholar
• Winterhalder R, Hoesly P, Delmore G, Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology 2011;80:29-33
   PubMed Web of Science ®Google Scholar
• Regnier Denois V, Poirson J, Nourissat A, Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care 2010;20:520-7
   PubMed Web of Science ®Google Scholar
• Simons S, Ringsdorf S, Braun M, Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 2011;19:1009-18
   PubMed Web of Science ®Google Scholar
• Weingart SN, Spencer J, Buia S, Medication safety of five oral chemotherapies: a proactive risk assessment. J Oncol Pract 2011;7:2-6
   PubMedGoogle Scholar
• Streeter SB, Lee Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 2011;7(Suppl 3):46S-51S
   PubMedGoogle Scholar
• Gebbia V, Bellavia G, Russo P, Treatment monitoring program implementation of adherence to erlotinib as second-line therapy for advanced non small cell lung carcinoma. Tumori 2010;10:S68
   Google Scholar
• Mayer EL, Partridge AH, Harris LN, Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat 2009;117:615-23
   PubMed Web of Science ®Google Scholar
• Timmers L, Boons CCLM, Mangnus D, The use of erlotinib in daily practice: a study on adherence and patients' experiences. BMC Cancer 2011;11:284
   PubMed Web of Science ®Google Scholar
• Banna GL, Collova E, Gebbia V, Anticancer oral therapy: emerging related issues. Cancer Treat Rev 2010;36:595-605
   PubMed Web of Science ®Google Scholar
• Viele CS. Managing oral chemotherapy: the healthcare practitioner's role. Am J Health Syst Pharm 2007;64:S25-32
   PubMed Web of Science ®Google Scholar
• Weingart SN, Flug J, Brouillard D, Oral chemotherapy safety practices at US cancer centres: questionnaire survey. Br Med J 2007;334:407
   PubMed Web of Science ®Google Scholar
• deLemos M. Adherence to therapy with oral agents. J Natl Cancer Inst 2002;94:1652
   Web of Science ®Google Scholar
• Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilization, costs, and patient outcomes. Cochrane Database Syst Rev 2000(3):CD000336
   Google Scholar
• Haynes RB, Yao X, Degani A, Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005(4):CD000011
   Google Scholar
• McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79
   PubMed Web of Science ®Google Scholar
• Hohneker J, Shah-Mehta S, Brandt PS. Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract 2011;7:65-7
   PubMedGoogle Scholar